Dr. Sulaiman Al Habib Medical Services Group: Has Growth Reached Its Ceiling—or Is the Next Chapter Just Beginning?
A strategic view of HMG’s growth ceiling, the opportunity for a new mass-market healthcare brand, and the potential expansion into Egypt, Morocco and Nigeria
There is a fascinating question emerging around Dr. Sulaiman Al Habib Medical Services Group (HMG): after building one of the strongest private healthcare platforms in Saudi Arabia and the wider Middle East, has the Group reached the natural limits of its existing business model?
My answer is not yet.
In fact, the more interesting possibility is that HMG may be approaching the limits of one particular model—premium, highly specialized, capital-intensive healthcare in Saudi Arabia—while simultaneously approaching an opportunity to create an entirely new growth curve.
The first half of 2026 provides an important signal.
HMG reported revenue of SAR 7.44 billion for H1 2026, representing growth of 13.76% compared with H1 2025. EBITDA increased 13.22% to SAR 1.90 billion, while net profit reached SAR 1.17 billion, up 1.56%. The relatively modest net-profit growth, despite strong revenue growth, was mainly attributed to fixed costs associated with recently launched hospitals that remain in their ramp-up phase.
This is not necessarily a sign of saturation.
It may instead be the financial signature of a company that has invested heavily ahead of demand.
HMG Has Not Reached Its Growth Ceiling—But Its Growth Model Is Changing
HMG has spent years building a premium healthcare proposition around large hospitals, sophisticated medical technology, Centers of Excellence, high-quality physicians and an integrated healthcare ecosystem.
The strategy has been remarkably successful.
By 2025, the Group had become one of the largest private healthcare providers in the Middle East, with a rapidly expanding network across Saudi Arabia and the UAE. Its strategy has also increasingly incorporated pharmacies, diagnostics, home healthcare, technology, revenue-cycle management and other healthcare solutions.
Its own corporate disclosures show that HMG’s subsidiary ecosystem now extends well beyond hospitals, including laboratories, primary healthcare centers, home healthcare, telemedicine, IT, revenue-cycle management and other healthcare-support businesses.
This diversification is strategically important.
HMG is becoming a healthcare platform, not simply a hospital operator.
And that distinction may determine its next decade of growth.
The First-Half 2026 Numbers Tell an Important Story
At first glance, H1 2026 could be interpreted as a period of slowing profitability.
Revenue increased by almost 14%, EBITDA by more than 13%, but net profit increased only 1.56%.
However, the Saudi Exchange disclosure explains that recently launched hospitals remain in the operational ramp-up phase, carrying fixed costs before reaching optimal utilization. Management expects their revenue contribution to increase progressively as utilization improves.
That distinction is crucial.
The question is not simply:
“Why did profit grow more slowly than revenue?”
The better question is:
“How much operating leverage will be released when the new capacity reaches mature utilization?”
If the newly launched hospitals achieve mature occupancy and procedure volumes, HMG could potentially experience another period of margin expansion without having to repeat the same level of capital investment.
In other words, part of today’s margin pressure may be the price of tomorrow’s capacity.
But There Is a Structural Question: How Much More Can Saudi Arabia Absorb?
This is where the discussion becomes more strategic.
Saudi Arabia remains a tremendous healthcare market. Vision 2030, demographic growth, increasing healthcare utilization, private-sector participation and the evolution of insurance and healthcare financing all support long-term demand.
But HMG has already established an exceptionally strong position.
The Group has built large hospitals, expanded into multiple Saudi regions and continued adding capacity. Its management has previously described a period of rapid expansion, including significant increases in bed capacity.
At some point, therefore, the economics of adding another premium hospital become different from the economics of entering a new market or serving a new patient segment.
This is where I believe HMG should consider its next strategic move.
The Missing Segment: Class B and C Healthcare
One of the most interesting strategic opportunities is the creation of a second healthcare brand targeting a broader socioeconomic segment.
The existing HMG brand is strongly associated with premium healthcare, advanced technology, sophisticated infrastructure and high clinical standards.
That positioning is extremely valuable.
But it can also create a strategic limitation.
A premium brand cannot always move down-market without risking brand dilution.
The solution may therefore be brand architecture rather than repositioning.
Instead of changing the HMG brand, the Group could create a separate brand designed specifically for the middle-income and mass-market population.
Conceptually:
HMG Premium Healthcare
Advanced tertiary care • Centers of Excellence • High-acuity hospitals • Premium patient experience
New Mass-Market Brand
Accessible healthcare • Efficient hospitals • Primary and secondary care • Diagnostics • Day surgery • Affordable pricing
This would allow HMG to address a much larger total addressable market without compromising the equity of its flagship brand.
The New Brand Should Not Be “Cheap Healthcare”
This distinction is extremely important.
A Class B/C healthcare brand should not be designed as a low-quality alternative.
It should be designed as a high-efficiency healthcare model.
The proposition could be:
- Standardized hospital design
- Smaller footprints
- Efficient operating theatres
- Strong emergency departments
- Primary and secondary care integration
- Diagnostics on-site
- Day-care surgery
- Shorter length of stay
- Digital registration and appointment systems
- Centralized procurement
- Standardized clinical protocols
- Lean administrative structures
- Strong physician productivity management
- Transparent and affordable pricing
The strategic objective would be simple:
“HMG Quality System + Lower Cost Operating Model.”
This could potentially unlock a much larger population segment.
Why a Second Brand Could Be a Game Changer
Healthcare markets are often polarized between premium private providers and fragmented low-cost providers.
The middle of the market can be underserved.
This is particularly true in emerging markets where patients want better quality, safety and reliability but cannot afford premium hospital pricing.
HMG already possesses many of the capabilities required to solve this problem:
- Clinical governance
- Brand credibility
- Physician networks
- Procurement scale
- Technology infrastructure
- Hospital management expertise
- Diagnostics
- Pharmacy infrastructure
- Digital healthcare
- Operational management
The missing component is essentially a different operating model and price architecture.
That could be developed through a new brand rather than by changing HMG itself.
Egypt Could Be One of the Most Attractive Expansion Opportunities
Egypt should be considered carefully because it represents a fundamentally different healthcare market from Saudi Arabia.
It combines a very large population, extensive physician resources, significant healthcare demand and a highly fragmented private healthcare sector.
For HMG, this could create an opportunity to deploy a model based on scale, efficiency and standardized healthcare delivery.
The Group would not necessarily need to reproduce the large Saudi hospital model.
A more attractive Egyptian strategy could be:
Polyclinics + Day Surgery + Diagnostics + Secondary Hospitals + Selected Centers of Excellence
This would allow HMG to build a network with a lower capital requirement per facility.
Egypt could also provide a strong talent ecosystem for physicians, nurses and healthcare professionals, combined with comparatively competitive operating costs.
The strategic opportunity would therefore be to combine:
Saudi Capital & Governance + Egyptian Medical Talent + HMG Operating System + Mass-Market Healthcare
Morocco: A Gateway to North and Francophone Africa
Morocco represents a different but potentially highly attractive opportunity.
Its geographical position provides access to North Africa and potentially to wider Francophone African healthcare markets.
For HMG, Morocco could serve as a regional platform rather than merely another individual country operation.
A Moroccan strategy could focus on:
- Private hospitals
- Specialized outpatient centers
- Diagnostics
- Women’s health
- Cardiology
- Orthopedics
- Oncology
- Medical tourism
- Healthcare management
However, Morocco should be approached through local partnerships and a strong understanding of its regulatory and reimbursement environment.
The opportunity is real, but it should be partnership-led rather than purely capital-led.
Nigeria: The Biggest Long-Term Bet
Nigeria may ultimately represent the largest opportunity of the three—but also the most complicated.
Its enormous population, urbanization, growing private healthcare demand and concentration of economic activity around cities such as Lagos and Abuja make it strategically attractive.
But Nigeria requires a different operating philosophy.
Rather than immediately building a large number of conventional hospitals, HMG could consider an asset-light model based on:
- Specialist outpatient centers
- Diagnostics
- Day surgery
- Primary healthcare
- Hospital management
- Digital healthcare
- Medical tourism links with Saudi Arabia and Egypt
- Joint ventures with established Nigerian healthcare operators
HMG’s brand could then become a quality benchmark rather than simply a hospital name.
The Regional Model Could Become Much Larger Than Hospital Ownership
This is where HMG’s existing diversification becomes particularly interesting.
The Group already has businesses and capabilities covering hospitals, pharmacies, diagnostics, home healthcare, primary healthcare, telemedicine, IT and revenue-cycle management.
That means the Group could theoretically export an entire healthcare operating system.
Imagine a model where HMG enters Egypt, Morocco or Nigeria through a combination of:
Hospital Management + Diagnostics + Pharmacy + Digital Healthcare + Primary Care + Centers of Excellence
Instead of buying everything, HMG could selectively own, operate, manage or partner depending on the market.
This would dramatically reduce the capital intensity of international expansion.
HMG’s Greatest Asset May Be Its Operating System
The most valuable asset that HMG could export internationally may not be its physical hospitals.
It may be its accumulated knowledge.
Over three decades, the Group has developed expertise in managing high-volume healthcare operations, complex clinical services, patient journeys, technology, medical professionals and large infrastructure.
HMG itself emphasizes Centers of Excellence and specialized care as core components of its model.
This creates an opportunity to transform operational know-how into a scalable commercial product.
In the future, HMG could potentially have three distinct engines:
- HMG Premium — tertiary and high-acuity healthcare.
- HMG Access — Class B/C efficient and affordable healthcare.
- HMG Solutions — management, technology, diagnostics, digital healthcare and healthcare infrastructure services.
That would be a significantly more powerful model than simply operating hospitals.
But International Expansion Has Serious Risks
The opportunity should not be confused with an easy expansion story.
Egypt, Morocco and Nigeria each have different currencies, regulations, reimbursement systems, physician structures, labor markets and political-economic environments.
HMG’s Saudi model cannot simply be copied and pasted into these markets.
The Group would need to localize:
- Pricing
- Hospital design
- Physician compensation
- Insurance relationships
- Procurement
- Workforce models
- Clinical pathways
- Technology
- Governance
- Patient experience
There is also a major capital-allocation question.
HMG’s H1 2026 results demonstrate that expansion has an initial financial cost: recently opened hospitals are carrying fixed costs while utilization builds.
International expansion could amplify this effect if the Group moves too aggressively.
Therefore, the next phase should be disciplined expansion rather than expansion for its own sake.
The Strategic Question Is Not “Where Should HMG Build Hospitals?”
The better question is:
“Where can HMG replicate its healthcare operating system at the highest return on invested capital?”
This changes the entire strategic discussion.
In some markets, the answer may be hospital ownership.
In others, it may be management contracts.
In others, joint ventures.
And in some markets, the best entry point may be diagnostics, primary care or a digital platform.
Tashawer Opinion: HMG May Be Approaching a Strategic Inflection Point
From a healthcare strategy perspective, I would not describe HMG as a company that has reached its growth ceiling.
I would describe it as a company that may be approaching the ceiling of its first growth model.
The Saudi premium hospital market can continue to generate growth, particularly as recently opened facilities mature. The first-half 2026 results clearly indicate that the Group still has substantial organic capacity embedded in its existing expansion program.
But the bigger opportunity may come from changing the architecture of growth.
HMG could move from one brand and one dominant market into a multi-brand, multi-market healthcare platform.
The creation of a Class B/C brand could unlock a massive new patient population.
Egypt could provide scale and medical talent.
Morocco could provide a gateway into North and Francophone Africa.
Nigeria could provide long-term demographic scale.
Saudi Arabia would remain the premium flagship and the financial and clinical center of gravity.
A Possible Future HMG Architecture
| Platform | Target | Strategic Role |
|---|---|---|
| HMG Premium | Premium / high-acuity patients | Centers of Excellence, tertiary care and advanced medicine |
| HMG Access | Class B & C | Affordable, standardized, high-efficiency healthcare |
| HMG Solutions | Healthcare operators and institutions | Technology, management, diagnostics, RCM and digital services |
| HMG International | MENA & Africa | Joint ventures, management contracts and selective ownership |
The Final Verdict
Has Sulaiman Al Habib reached its growth ceiling?
Not in my view.
But the nature of growth must change.
The first chapter was about building the strongest premium healthcare platform in Saudi Arabia.
The second chapter is about optimizing the enormous capacity already created.
The third chapter could be much bigger:
Premium Healthcare + Mass-Market Healthcare + Healthcare Solutions + International Expansion.
If HMG successfully develops a separate Class B/C brand while preserving the premium positioning of its flagship brand, it could dramatically expand its total addressable market.
If it then combines that model with disciplined expansion into Egypt, Morocco and Nigeria, the Group could move from being primarily a Saudi/Gulf healthcare champion toward becoming a genuinely MENA-Africa healthcare platform.
The strategic opportunity is therefore not simply to build more hospitals.
It is to turn HMG’s accumulated clinical expertise, operating discipline, technology, procurement scale and brand equity into a scalable healthcare platform that can serve different income segments and different countries.
That, in my opinion, is where the next major growth curve could come from.
The question is not whether HMG has reached the end of its growth story.
The real question is whether HMG is ready to write a completely different next chapter.
Editorial Perspective — Tashawer Healthcare & Healthcare Business Advisory
Note: The discussion of a new Class B/C brand and expansion into Egypt, Morocco and Nigeria represents a strategic scenario and Tashawer perspective, not a statement that HMG has publicly announced such a strategy. HMG’s current disclosed subsidiaries and operations remain concentrated in Saudi Arabia and the UAE.
